 Maryam Shakiba
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Iran | 11 | 2024 | 36 | 0.700 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 1726 | 0.690 |
Why?
| | Obesity, Abdominal | 2 | 2018 | 37 | 0.630 |
Why?
| | Nutritional Status | 1 | 2021 | 286 | 0.620 |
Why?
| | Coronary Disease | 2 | 2018 | 348 | 0.610 |
Why?
| | Antibodies, Viral | 2 | 2021 | 520 | 0.600 |
Why?
| | Obesity | 3 | 2019 | 2505 | 0.550 |
Why?
| | Carbolines | 1 | 2012 | 27 | 0.390 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 38 | 0.380 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 82 | 0.380 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 38 | 0.380 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2012 | 47 | 0.360 |
Why?
| | Stroke | 1 | 2019 | 1019 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2087 | 0.340 |
Why?
| | Oral Health | 2 | 2022 | 139 | 0.330 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 122 | 0.330 |
Why?
| | Hypertension | 2 | 2013 | 1052 | 0.260 |
Why?
| | Glucose | 2 | 2023 | 899 | 0.230 |
Why?
| | Nephrostomy, Percutaneous | 2 | 2016 | 9 | 0.220 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 4402 | 0.220 |
Why?
| | Humans | 27 | 2024 | 114043 | 0.220 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 137 | 0.220 |
Why?
| | Mass Screening | 1 | 2010 | 979 | 0.220 |
Why?
| | Middle Aged | 15 | 2020 | 26605 | 0.220 |
Why?
| | Kidney Calculi | 2 | 2016 | 30 | 0.220 |
Why?
| | Heart Failure | 1 | 2016 | 1958 | 0.220 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 65 | 0.220 |
Why?
| | Algorithms | 1 | 2010 | 1469 | 0.210 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2014 | 18 | 0.210 |
Why?
| | Risk Factors | 9 | 2023 | 8614 | 0.210 |
Why?
| | Male | 16 | 2020 | 55396 | 0.190 |
Why?
| | Ureteral Calculi | 2 | 2011 | 13 | 0.180 |
Why?
| | Publications | 1 | 2021 | 37 | 0.180 |
Why?
| | Chamomile | 1 | 2020 | 1 | 0.180 |
Why?
| | Health Education | 1 | 2024 | 317 | 0.180 |
Why?
| | Female | 17 | 2024 | 59325 | 0.180 |
Why?
| | Phytotherapy | 1 | 2020 | 67 | 0.170 |
Why?
| | Volatilization | 1 | 2019 | 49 | 0.170 |
Why?
| | Family Characteristics | 1 | 2020 | 151 | 0.160 |
Why?
| | Leiomyoma | 1 | 2019 | 44 | 0.160 |
Why?
| | Body Size | 1 | 2019 | 90 | 0.160 |
Why?
| | Double-Blind Method | 5 | 2020 | 1656 | 0.160 |
Why?
| | Uterine Neoplasms | 1 | 2019 | 73 | 0.160 |
Why?
| | Rhinitis | 1 | 2020 | 128 | 0.160 |
Why?
| | Plant Extracts | 1 | 2020 | 154 | 0.160 |
Why?
| | Income | 1 | 2019 | 167 | 0.150 |
Why?
| | Sinusitis | 1 | 2020 | 174 | 0.150 |
Why?
| | Logistic Models | 2 | 2021 | 1829 | 0.150 |
Why?
| | Public Health | 1 | 2022 | 433 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1080 | 0.140 |
Why?
| | Prospective Studies | 6 | 2019 | 6195 | 0.130 |
Why?
| | Patient Positioning | 1 | 2016 | 41 | 0.130 |
Why?
| | Causality | 1 | 2016 | 104 | 0.130 |
Why?
| | Fluoroscopy | 1 | 2016 | 139 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1011 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 120 | 0.120 |
Why?
| | Supine Position | 2 | 2016 | 32 | 0.120 |
Why?
| | Lipoproteins, HDL | 1 | 2015 | 76 | 0.120 |
Why?
| | Kidney Transplantation | 1 | 2020 | 538 | 0.120 |
Why?
| | Models, Statistical | 1 | 2018 | 595 | 0.120 |
Why?
| | Incidence | 2 | 2020 | 2314 | 0.110 |
Why?
| | Blood Glucose | 1 | 2023 | 1827 | 0.110 |
Why?
| | Urinary Retention | 1 | 2014 | 19 | 0.110 |
Why?
| | Mastoid | 1 | 2013 | 15 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2020 | 754 | 0.110 |
Why?
| | Otologic Surgical Procedures | 1 | 2013 | 16 | 0.110 |
Why?
| | Sulfonamides | 2 | 2014 | 444 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2016 | 342 | 0.110 |
Why?
| | Survival Analysis | 1 | 2016 | 1206 | 0.110 |
Why?
| | Triglycerides | 1 | 2015 | 467 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2013 | 102 | 0.100 |
Why?
| | Papaverine | 1 | 2012 | 2 | 0.100 |
Why?
| | Albuminuria | 1 | 2013 | 164 | 0.100 |
Why?
| | Renal Colic | 1 | 2012 | 3 | 0.100 |
Why?
| | Tadalafil | 1 | 2012 | 7 | 0.100 |
Why?
| | Pain, Postoperative | 1 | 2013 | 190 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2020 | 9049 | 0.100 |
Why?
| | Comorbidity | 1 | 2016 | 1447 | 0.100 |
Why?
| | Weight Loss | 1 | 2016 | 642 | 0.100 |
Why?
| | Flank Pain | 1 | 2011 | 5 | 0.090 |
Why?
| | Placebos | 1 | 2012 | 197 | 0.090 |
Why?
| | Prazosin | 1 | 2011 | 24 | 0.090 |
Why?
| | Urination Disorders | 1 | 2011 | 11 | 0.090 |
Why?
| | Acute Pain | 1 | 2012 | 35 | 0.090 |
Why?
| | Otitis Media | 1 | 2013 | 142 | 0.090 |
Why?
| | Isosorbide | 1 | 2011 | 1 | 0.090 |
Why?
| | Prone Position | 1 | 2010 | 27 | 0.090 |
Why?
| | Analgesics | 1 | 2012 | 156 | 0.090 |
Why?
| | Lithotripsy | 1 | 2010 | 40 | 0.090 |
Why?
| | Chronic Pain | 1 | 2013 | 208 | 0.090 |
Why?
| | Anthropometry | 1 | 2010 | 183 | 0.080 |
Why?
| | Cohort Studies | 1 | 2019 | 4883 | 0.080 |
Why?
| | Institutionalization | 1 | 2009 | 12 | 0.080 |
Why?
| | Tooth Diseases | 1 | 2009 | 13 | 0.080 |
Why?
| | Mouth Diseases | 1 | 2009 | 40 | 0.080 |
Why?
| | Prognosis | 1 | 2016 | 3315 | 0.080 |
Why?
| | Stents | 1 | 2011 | 466 | 0.070 |
Why?
| | Neoplasms | 1 | 2020 | 2086 | 0.070 |
Why?
| | Quality of Life | 2 | 2020 | 2343 | 0.070 |
Why?
| | Pain Measurement | 3 | 2013 | 441 | 0.060 |
Why?
| | Aged | 5 | 2020 | 18969 | 0.060 |
Why?
| | Chronic Disease | 3 | 2020 | 1577 | 0.060 |
Why?
| | Body Mass Index | 3 | 2019 | 1957 | 0.060 |
Why?
| | Kidney | 1 | 2010 | 1182 | 0.060 |
Why?
| | Adult | 8 | 2020 | 30375 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2014 | 2122 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 12 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 492 | 0.050 |
Why?
| | Cities | 1 | 2021 | 80 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2020 | 75 | 0.040 |
Why?
| | Bias | 1 | 2021 | 178 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3003 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 70 | 0.040 |
Why?
| | Adolescent | 3 | 2014 | 17800 | 0.040 |
Why?
| | Age Factors | 2 | 2019 | 2885 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2012 | 949 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2019 | 307 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2537 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 4595 | 0.040 |
Why?
| | Waist Circumference | 1 | 2016 | 122 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 635 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1204 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1168 | 0.030 |
Why?
| | Premenopause | 1 | 2015 | 105 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 308 | 0.030 |
Why?
| | Varicocele | 1 | 2014 | 10 | 0.030 |
Why?
| | Scrotum | 1 | 2014 | 23 | 0.030 |
Why?
| | Herniorrhaphy | 1 | 2014 | 47 | 0.030 |
Why?
| | Operative Time | 1 | 2014 | 106 | 0.030 |
Why?
| | Postmenopause | 1 | 2015 | 301 | 0.030 |
Why?
| | Postoperative Period | 1 | 2013 | 288 | 0.030 |
Why?
| | Suppositories | 1 | 2012 | 3 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 6077 | 0.020 |
Why?
| | Diclofenac | 1 | 2012 | 14 | 0.020 |
Why?
| | Hematuria | 1 | 2011 | 7 | 0.020 |
Why?
| | Nocturia | 1 | 2011 | 7 | 0.020 |
Why?
| | Child | 1 | 2010 | 18400 | 0.020 |
Why?
| | Parasympatholytics | 1 | 2011 | 13 | 0.020 |
Why?
| | Celecoxib | 1 | 2011 | 38 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 370 | 0.020 |
Why?
| | Placebo Effect | 1 | 2011 | 52 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2011 | 80 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 951 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 158 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 12521 | 0.020 |
Why?
| | Stomatitis, Denture | 1 | 2009 | 1 | 0.020 |
Why?
| | Tongue, Fissured | 1 | 2009 | 1 | 0.020 |
Why?
| | Mouth Floor | 1 | 2009 | 6 | 0.020 |
Why?
| | Burning Mouth Syndrome | 1 | 2009 | 5 | 0.020 |
Why?
| | Mouth, Edentulous | 1 | 2009 | 10 | 0.020 |
Why?
| | Xerostomia | 1 | 2009 | 19 | 0.020 |
Why?
| | Varicose Veins | 1 | 2009 | 14 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1422 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 296 | 0.020 |
Why?
| | Tongue | 1 | 2009 | 66 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 907 | 0.020 |
Why?
| | Periodontal Diseases | 1 | 2009 | 54 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 152 | 0.020 |
Why?
| | Colon | 1 | 2010 | 232 | 0.020 |
Why?
| | Nursing Homes | 1 | 2009 | 138 | 0.020 |
Why?
| | Dental Caries | 1 | 2009 | 162 | 0.020 |
Why?
| | Young Adult | 2 | 2014 | 10444 | 0.020 |
Why?
| | Pyrazoles | 1 | 2011 | 361 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2384 | 0.020 |
Why?
| | Sex Factors | 1 | 2009 | 1706 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 2958 | 0.010 |
Why?
| | Prevalence | 1 | 2009 | 2247 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2009 | 6306 | 0.010 |
Why?
|
|
Shakiba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|